Nuclear microenvironments in cancer diagnosis and treatment

Journal of Cellular Biochemistry

Volumn 104, Issue 6, 2008, Pages 1953-1963

  Pezo, Rossanna C ^a   Singer, Robert H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer; Gene expression; Nuclear architecture

Indexed keywords

CASEIN KINASE II; CASEIN KINASE II INHIBITOR; ENZYME INHIBITOR; HISTONE DEACETYLASE INHIBITOR; IMATINIB; NUCLEOPHOSMIN; PROTEASOME INHIBITOR; RETINOIC ACID; TRICHOSTATIN A; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LYMPHOMA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL NUCLEUS; CELL PROLIFERATION; CHROMATIN; CHROMOSOME; CHRONIC MYELOID LEUKEMIA; COLON CANCER; CONFERENCE PAPER; GENE EXPRESSION; HUMAN; MUTATION; NONHUMAN; NUCLEOLUS; PRIORITY JOURNAL; PROSTATE CANCER; T CELL LYMPHOMA; CELL COMPARTMENTALIZATION; GENETIC TRANSCRIPTION; GENETICS; INTERPHASE; NEOPLASM; PATHOLOGY; REVIEW;

CELL COMPARTMENTATION; CELL NUCLEUS; CELL NUCLEUS STRUCTURES; HUMANS; INTERPHASE; NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 49049088112     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21353     Document Type: Conference Paper

References (70)

1. Arabi A, Wu S, Ridderstrale K, Bierhoff H, Shiue C, Fatyol K, Fahlen S, Hydbring P, Soderberg O, Grummt I, Larsson LG, Wright AP. 2005. c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. Nat Cell Biol 7:303-310.
2. Bartova E, Kozubek S, Kozubek M, Jirsova P, Lukasova E, Skalnikova M, Buchnickova K. 2000. The influence of the cell cycle, differentiation and irradiation on the nuclear location of the abl, bcr and c-myc genes in human leukemic cells. Leuk Res 24:233-241.
3. Bernardi R, Pandolfi PP. 2003. Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene 22:9048-9057.
4. Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP. 2004. PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nat Cell Biol 6:665-672.
5. Borrow J, Goddard AD, Sheer D, Solomon E. 1990. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 249:1577-15780.
6. Branco MR, Pombo A. 2006. Intermingling of chromosome territories in interphase suggests role in translocations and transcription-dependent associations. PLoS Biol 4:e138.
7. Brown JM, Leach J, Reittie JE, Atzberger A, Lee-Prudhoe J, Wood WG, Higgs DR, Iborra FJ, Buckle VJ. 2006. Coregulated human globin genes are frequently in spatial proximity when active. J Cell Biol 172:177-187.
8. Capodieci P, Donovan M, Buchinsky H, Jeffers Y, Cordon-Cardo C, Gerald W, Edelson J, Shenoy SM, Singer RH. 2005. Gene expression profiling in single cells within tissue. Nat Methods 2:663-665.
9. Chubb JR, Trcek T, Shenoy SM, Singer RH. 2006. Transcriptional pulsing of a developmental gene. Curr Biol 16:1018-1025.
10. Colombo E, Martinelli P, Zamponi R, Shing DC, Bonetti P, Luzi L, Volorio S, Bernard L, Pruneri G, Alcalay M, Pelicci PG. 2006. Derealization and destabilization of the Arf tumor suppressor by the leukemia-associated NPM mutant. Cancer Res 66:3044-3050.
11. Cremer M, Kupper K, Wagler B, Wizelman L, von Hase J, Weiland Y, Kreja L, Diebold J, Speicher MR, Cremer T. 2003. Inheritance of gene density-related higher order chromatin arrangements in normal and tumor cell nuclei. J Cell Biol 162:809-820.
12. Cremer T, Cremer M, Dietzel S, Muller S, Solovei I, Fakan S. 2006. Chromosome territories-A functional nuclear landscape. Curr Opin Cell Biol 18:307-316.
13. de Stanchina E, Querido E, Narita M, Davuluri RV, Pandolfi PP, Ferbeyre G, Lowe SW. 2004. PML is a direct p53 target that modulates p53 effector functions. Mol Cell 13:523-535.
14. de The H, Chomienne C, Lanotte M, Degos L, Dejean A. 1990. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 347:558-561.
15. Debes JD, Schmidt LJ, Huang H, Tindall DJ. 2002. p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62:5632-5636.
16. Debes JD, Sebo TJ, Lohse CM, Murphy LM, Haugen DA, Tindall DJ. 2003. p300 in prostate cancer proliferation and progression. Cancer Res 63:7638-7640.
17. Debes JD, Sebo TJ, Heemers HV, Kipp BR, Haugen DL, Lohse CM, Tindall DJ. 2005. p300 modulates nuclear morphology in prostate cancer. Cancer Res 65:708-712.
18. Deininger MW, Goldman JM, Lydon N, Melo JV. 1997. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691-3698.
19. Deininger MW, Vieira S, Mendiola R, Schultheis B, Goldman JM, Melo JV. 2000. BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res 60:2049-2055.
20. DeMay RM. 1996. The art and science of cytopathology. Chicago: American Society of Clinical Pathologists Press.
21. Dimitrova DS, Berezney R. 2002. The spatio-temporal organization of DNA replication sites is identical in primary, immortalized and transformed mammalian cells. J Cell Sci 115:4037-4051.
22. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566.
23. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF. 2005. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266.
24. Falini B, Nicoletti I, Martelli MF, Mecucci C. 2007. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+AML): Biologic and clinical features. Blood 109:874-885.
25. Fogal V, Gostissa M, Sandy P, Zacchi P, Sternsdorf T, Jensen K, Pandolfi PP, Will H, Schneider C, Del Sal G. 2000. Regulation of p53 activity in nuclear bodies by a specific PML isoform. Embo J 19:6185-6195.
26. Francastel C, Walters MC, Groudine M, Martin DI. 1999. A functional enhancer suppresses silencing of a transgene and prevents its localization close to centrometric heterochromatin. Cell 99:259-269.
27. Gambacorta M, Flenghi L, Fagioli M, Pileri S, Leoncini L, Bigerna B, Pacini R, Tanci LN, Pasqualucci L, Ascani S, Mencarelli A, Liso A, Pelicci PG, Falini B. 1996. Heterogeneous nuclear expression of the promyelocytic leukemia (PML) protein in normal and neoplastic human tissues. Am J Pathol 149:2023-2035.
28. Goldman JM, Melo JV. 2003. Chronic myeloid leukaemia - Advances in biology and new approaches to treatment. N Engl J Med 349:1451-1464.
29. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG. 1998. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815-818.
30. Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, Pandolfi PP. 2005. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 437:147-153.
31. Grisendi S, Mecucci C, Falini B, Pandolfi PP. 2006. Nucleophosmin and cancer. Nat Rev Cancer 6:493.
32. Guo A, Salomoni P, Luo J, Shih A, Zhong S, Gu W, Pandolfi PP. 2000. The function of PML in p53-dependent apoptosis. Nat Cell Biol 2:730-736.
33. Gurrieri C, Capodieci P, Bernardi R, Scaglioni PP, Nafa K, Rush LJ, Verbel DA, Cordon-Cardo C, Pandolfi PP. 2004. Loss of the tumor suppressor PML in human cancers of multiple histologic origins. J Natl Cancer Inst 96:269-279.
34. Harris NL, Stein H, Coupland SE, Hummel M, Favera RD, Pasqualucci L, Chan WC. 2001. New approaches to lymphoma diagnosis. Hematol Am Soc Hematol Educ Program 194-220.
35. Hochhaus A, Reiter A, Skladny H, Melo JV, Sick C, Berger U, Guo JQ, Arlinghaus RB, Hehlmann R, Goldman JM, Cross NC. 1996. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia. Blood 88:2236-2240.
36. Huang ME, Yu-chen Y, Shu-rong C, Jin-ren C, Jia-Xiang L, Long-jun G, Zhen-yi W. 1988. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572.
37. Kosak ST, Groudine M. 2004. Gene order and dynamic domains. Science 306:644-647.
38. Kosak ST, Skok JA, Medina KL, Riblet R, Le Beau MM, Fisher AG, Singh H. 2002. Subnuclear compartmentalization of immunoglobulin loci during lymphocyte development. Science 296:158-162.
39. Lallemand-Breitenbach V, de The H. 2006. CK2 and PML: Regulating the regulator. Cell 126:244-245.
40. Lanctot C, Cheutin T, Cremer M, Cavalli G, Cremer T. 2007. Dynamic genome architecture in the nuclear space: Regulation of gene expression in three dimensions. Nat Rev Genet 8:104-115.
41. Ie Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C. 1999. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 91:163-168.
42. Levsky JM, Shenoy SM, Pezo RC, Singer RH. 2002. Single-cell gene expression profiling. Science 297:836-840.
43. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH, Jr., Evans RM. 1998. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811-814.
44. Mayer C, Bierhoff H, Grummt I. 2005. The nucleolus as a stress sensor: JNK2 inactivates the transcription factor TIF-IA and down-regulates rRNA synthesis. Genes Dev 19:933-941.
45. Melnick A, Licht JD. 1999. Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93:3167-3215.
46. Melo JV, Gordon DE, Cross NC, Goldman JM. 1993. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 81:158-165.
47. Misteli T. 2004. Spatial positioning: A new dimension in genome function. Cell 119:153-156.
48. Misteli T. 2007. Beyond the sequence: Cellular organization of genome function. Cell 128:787-800.
49. Osborne CS, Chakalova L, Brown KE, Carter D, Horton A, Debrand E, Goyenechea B, Mitchell JA, Lopes S, Reik W, Fraser P. 2004. Active genes dynamically colocalize to shared sites of ongoing transcription. Nat Genet 36:1065-1071.
50. Ragoczy T, Bender MA, Telling A, Byron R, Groudine M. 2006. The locus control region is required for association of the murine beta-globin locus with engaged transcription factories during erythroid maturation. Genes Dev 20:1447-1457.
51. Roix JJ, McQueen PG, Munson PJ, Parada LA, Misteli T. 2003. Spatial proximity of translocation-prone gene loci in human lymphomas. Nat Genet 34:287-291.
52. Rubbi CP, Milner J. 2003. Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses. Embo J 22:6068-6077.
53. Scaglioni PP, Yung TM, Cai LF, Erdjument-Bromage H, Kaufman AJ, Singh B, Teruya-Feldstein J, Tempst P, Pandolfi PP. 2006. A CK2-dependent mechanism for degradation of the PML tumor suppressor. Cell 126:269-283.
54. Schnapp A, Pfleiderer C, Rosenbauer H, Grummt I. 1990. A growth-dependent transcription initiation factor (TIF-IA) interacting with RNA polymerase I regulates mouse ribosomal RNA synthesis. Embo J 9:2857-2863.
55. Siebert R, Rosenwald A, Staudt LM, Morris SW. 2001. Molecular features of B-cell lymphoma. Curr Opin Oncol 13:316-324.
56. Trotman LC, Alimonti A, Scaglioni PP, Koutcher JA, Cordon-Cardo C, Pandolfi PP. 2006. Identification of a tumour suppressor network opposing nuclear Akt function. Nature 441:523-527.
57. Trus MR, Yang L, Suarez Saiz F, Bordeleau L, Jurisica I, Minden MD. 2005. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 19:1161.
58. Tsai RY, McKay RD. 2002. A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev 16:2991-3003.
59. Vigushin DM, Coombes RC. 2002. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13:1-13.
60. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP. 1998. PML is essential for multiple apoptotic pathways. Nat Genet 20:266-272.
61. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. 1999. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1:20-26.
62. Willis TG, Dyer MJ. 2000. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood 96:808-822.
63. Yuan X, Zhou Y, Casanova E, Chai M, Kiss E, Grone HJ, Schutz G, Grummt I. 2005. Genetic inactivation of the transcription factor TIF-IA leads to nucleolar disruption, cell cycle arrest, and p53-mediated apoptosis. Mol Cell 19:77-87.
64. Zhang P, Chin W, Chow LT, Chan AS, Yim AP, Leung SF, Mok TS, Chang KS, Johnson PJ, Chan JY. 2000. Lack of expression for the suppressor PML in human small cell lung carcinoma. Int J Cancer 85:599-605.
65. Zhong S, Salomoni P, Pandolfi PP. 2000. The transcriptional role of PML and the nuclear body. Nat Cell Biol 2:E85-E90.
66. Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de The H. 1997. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:3978-3983.
67. Zhu J, Gianni M, Kopf E, Honore N, Chelbi-Alix M, Koken M, Quignon F, Rochette-Egly C, de The H. 1999. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. Proc Natl Acad Sci USA 96:14807-14812.
68. Zhu J, Lallemand-Breitenbach V, de The H. 2001. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 20:7257-7265.
69. Zink D, Amaral MD, Englmann A, Lang S, Clarke LA, Rudolph C, Alt F, Luther K, Braz C, Sadoni N, Rosenecker J, Schindelhauer D. 2004a. Transcription-dependent spatial arrangements of CFTR and adjacent genes in human cell nuclei. J Cell Biol 166:815-825.
70. Zink D, Fischer AH, Nickerson JA. 2004b. Nuclear structure in cancer cells. Nat Rev Cancer 4:677-687.